01—Abstract
Summary
Summary of the 10-Q filed August 6, 2010. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a net loss of $1.85 milliona for the first six months of 2010, a widening from the $1.19 million loss in the same period of 2009.
This was driven by a 7.5% decrease in net sales to $42.96 millionb, impacted by a significant drop in international orders and reduced sales of key products like the TASER X26 and single cartridges. Despite the revenue decline, the company saw some positive signs, including an increase in domestic sales in the first quarter of 2010, potentially linked to federal stimulus funding.
The company is also investing in new product lines and technology, such as EVIDENCE.com, which contributed to a decrease in R&D expenses due to capitalization of software development costs. While the company's cash position decreased, it maintains a strong liquidity position with $40.6 millionc in cash and cash equivalents and an undrawn $10 million line of credit, suggesting it is adequately resourced to fund its operations and strategic initiatives.
02—Key points
Key Highlights
- Net sales declined by 7.5% to $42.96 million for the first six months of 2010 compared to $46.44 million in the prior year period.
- The company reported a net loss of $1.85 million for the six months ended June 30, 2010, an increase from the $1.19 million net loss in the same period of 2009.
- Gross margin decreased to 53.8% from 61.1% due to increased cost of products sold as a percentage of net sales, driven by product mix, new product yields, and higher operational costs.
- Sales, General, and Administrative (SG&A) expenses decreased by 8.8% to $20.31 million, reflecting cost-control measures and reduced legal and consulting fees.
- Research and Development (R&D) expenses decreased by 16.2% to $7.20 million, with a portion of software development costs for EVIDENCE.com being capitalized.
- Cash and cash equivalents stood at $40.6 million at June 30, 2010, a decrease of $4.9 million from year-end 2009, primarily due to cash used in operations and investments.
- The company had no outstanding borrowings on its $10 million revolving credit facility, which was renewed through June 30, 2011.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2010, Axon Enterprise, Inc. lost $0.07.
- Revenue$19.1M100.0%
- Cost of revenue−$9.5M49.6%
- Gross profit$9.6M50.4%
- Operating costs−$13.1M68.3%
- Operating income−$3.4M18.0%
- Interest, other & tax$2.1M10.9%
- Net income−$1.4M7.1%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2010filed August 6, 2010Financial Statements
| Revenue | $19.12M |
| Cost of Revenue | $9.49M |
| Gross Profit | $9.63M |
| R&D Expenses | $3.06M |
| SG&A Expenses | $9.99M |
| Operating Income | -$3.44M |
| Net Income | -$1.36M |
| EPS (Basic) | $-0.02 |
| EPS (Diluted) | $-0.02 |
| Shares Outstanding (Basic) | 62.33M |
| Shares Outstanding (Diluted) | 62.33M |
05—Questions
Frequently Asked Questions
What was the company's revenue performance in the first half of 2010?
Net sales decreased by 7.5% to $42.96 million for the first six months of 2010, compared to $46.44 million in the same period of 2009. This decline was primarily attributed to a reduction in international orders and decreased sales of key products like the TASER X26 and single cartridges.
What is the company's profitability status?
The company reported a net loss of $1.85 million for the first six months of 2010, which is a wider loss compared to the $1.19 million net loss recorded in the first half of 2009. This was influenced by lower gross margins and a higher cost of products sold as a percentage of net sales.
How is the company managing its expenses?
Axon Enterprise, Inc. has implemented cost-control measures, resulting in a decrease in Sales, General, and Administrative (SG&A) expenses by 8.8%. Research and Development (R&D) expenses also decreased by 16.2%, partly due to the capitalization of software development costs for its EVIDENCE.com platform.
What is the company's current financial liquidity?
The company maintains a healthy liquidity position, with $40.6 million in cash and cash equivalents as of June 30, 2010. Additionally, it has access to an undrawn $10 million revolving credit facility, which was renewed through June 30, 2011, indicating sufficient resources to fund operations and strategic initiatives.
06—Continue